TriangleNCT01980888 · CITED IN SOURCE DOCUMENTS
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- TERMINATED
- Registry last update
- 2018-11-19
The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Key Inclusion Criteria: * Documented diagnosis of B-cell CLL, with diagnosis established according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) * No prior therapy for CLL other than corticosteroids for disease complications * CLL that warrants treatment * Presence of measurable lymphadenopathy * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 Key Exclusion Criteria: * Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation) * Known presence of myelodysplastic syndrome * Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization * Ongoing liver injury * History of non-infectious pneumonitis * Ongoing inflammatory bowel disease * History of prior allogeneic bone marrow progenitor cell or solid organ transplantation * Ongoing immunosuppressive therapy other than corticosteroids * Received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization Note: Other protocol defined Inclusion/Exclusion criteria may apply.
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
- intervention Names
- Drug: Idelalisib
- Drug: Bendamustine
- Drug: Rituximab
- label
- Idelalisib+bendamustine+rituximab
- type
- EXPERIMENTAL
- description
- Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
- intervention Names
- Drug: Bendamustine
- Drug: Rituximab
- Drug: Placebo
- label
- Placebo+bendamustine+rituximab
- type
- PLACEBO_COMPARATOR
- interventions
- arm Group Labels
- Idelalisib+bendamustine+rituximab
- description
- 150 mg tablet administered orally twice daily
- name
- Idelalisib
- other Names
- Zydelig®
- GS-1101
- CAL-101
- type
- DRUG
- arm Group Labels
- Idelalisib+bendamustine+rituximab
- Placebo+bendamustine+rituximab
- description
- Administered intravenously at a starting dose of 90 mg/m\^2 for up to 6 cycles. Dosing will be based on mg/m\^2 of body surface area.
- name
- Bendamustine
- type
- DRUG
- arm Group Labels
- Idelalisib+bendamustine+rituximab
- Placebo+bendamustine+rituximab
- description
- Single-use vials administered intravenously weekly starting at 375 mg/m\^2 on Day 1 (Week 0) and 500 mg/m\^2 thereafter for a total of 6 infusions
- name
- Rituximab
- type
- DRUG
- arm Group Labels
- Placebo+bendamustine+rituximab
- description
- Placebo to match idelalisib administered orally twice daily
- name
- Placebo
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- DOUBLE
- who Masked
- PARTICIPANT
- INVESTIGATOR
- primary Purpose
- TREATMENT
Enrollment
- count
- 311
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC).
- measure
- Progression-Free Survival
- time Frame
- Up to 22 months
- secondary Outcomes
- description
- Overall response rate (ORR) is defined as the proportion of participants who achieve a confirmed complete or partial response. ORR was to be assessed by an IRC.
- measure
- Overall Response Rate
- time Frame
- Up to 22 months
- description
- Nodal response rate is defined as the proportion of participants who achieve a 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of index lesions. Nodal response rate was to be assessed by an IRC.
- measure
- Nodal Response Rate
- time Frame
- Up to 22 months
- description
- Complete response rate is defined as the proportion of participants who achieve a confirmed complete response. Complete response rate was to be assessed by an IRC.
- measure
- Complete Response Rate
- time Frame
- Up to 22 months
- description
- Overall survival is defined as the interval from randomization to death from any cause. Overall survival was to be assessed by an IRC.
- measure
- Overall Survival
- time Frame
- Up to 22 months
- description
- Minimal residual disease (MRD) negativity rate is defined as the proportion of participants with MRD \< 10\^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab or bendamustine (whichever is later) for participants receiving the final dose of rituximab after the original scheduled date. MRD negativity rate was to be assessed by an IRC.
- measure
- Minimal Residual Disease Negativity Rate at Week 36
- time Frame
- Up to 22 months
Full study description
- brief Summary
- The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab treatment as standard of care. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated this study in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA).
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-254e5d2fab5dbd54fe83
- requested nct id
- NCT01980888
- primary nct id
- NCT01980888
- source kind
- fda_spl_label
- source record id
- ca3e7112-6dfe-403f-af6f-a0051e77d125
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- b26df66510a09aff65f560f92847a2ca3389b1efc032ef068f29e671626ba361
- payload
- application numbers
- NDA205858
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-254e5d2fab5dbd54fe83
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01980888
- occurrences
- context exact
- osure to Zydelig in three randomized, double-blind clinical trials (Studies 312-0123, 313-0124, and 313-0125) in patients with CLL and iNHL. In Study 312-0123 (NCT01980888), 311 patients with previously untreated CLL received up to 6 cycles of BR with or without Zydelig 150 mg twice daily. In Study 313-0124 (NCT01732913), 295 pat
- end
- 10226
- exact text
- NCT01980888
- start
- 10215
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/66/adverse_reactions/0
- source kind
- fda_spl_label
- source record id
- ca3e7112-6dfe-403f-af6f-a0051e77d125
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f01b4769db899a9d9372acd0f33a6bf22de26134e2166b59a73683f3e43e3379
- spl effective time
- 20250220
- spl set id
- efbdafa9-d18c-4e85-b4a2-1e620fc74e50
Preserved source evidence · Not medical advice